EXACT SCIENCES CORP Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash provided by operating activities:
Loss on disposal of property, plant and equipment
Unrealized (gain) loss on equity investments
Depreciation
Equity Securities, FV-NI, Gain (Loss)
Deferred tax benefit
Share-Based Payment Arrangement, Noncash Expense
Post-combination expense for acceleration of unvested equity
Realized gain on preferred stock investment
Realized (gain) loss on non-marketable investments
Loss on settlement of convertible notes
Amortization of deferred financing costs, convertible note debt discount and issuance costs, and other liabilities
Amortization of premium on short-term investments
Gain on settlements of convertible notes, net
Amortization of Intangible Assets
Intangible asset impairment charge
Asset acquisition IPR&D expense
Loss on sale of asset
Impairment of long-lived and indefinite-lived assets
Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff
Gain (Loss) On Contingent Consideration From Disposition Of Asset
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability
Non-cash lease expense
Other Noncash Income (Expense)

Changes in assets and liabilities, net of effects of acquisition:
Accounts receivable, net
Inventory, net
Operating lease liabilities
Accounts payable and accrued liabilities
Other assets and liabilities
Increase (Decrease) in Other Operating Assets
Increase (Decrease) in Other Operating Liabilities
Total other assets and liabilities

Net cash provided by operating activities
Cash flows from investing activities:
Purchases of marketable securities
Maturities and sales of marketable securities
Purchases of property, plant and equipment
Proceeds from Sale of Productive Assets
Proceeds From Contingent Consideration Receivable
Proceeds From Sale Of Investments In Privately-Held Companies
Payments to Acquire Other Investments
Business combination, net of cash acquired and issuance costs
Asset acquisitions, net of cash acquired
Other investing activities
Net cash provided by (used in) investing activities
Cash flows from financing activities:
Proceeds from Accounts Receivable Securitization
Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised
Proceeds from sale of common stock, net of issuance costs
Proceeds in connection with the Company's employee stock purchase plan
Payments on settlement of convertible notes
Payments on construction loan
Proceeds from issuance of convertible notes
Repayments of Accounts Receivable Securitization
Repayments of convertible debt
Payment, Tax Withholding, Share-Based Payment Arrangement
Payment for Contingent Consideration Liability, Financing Activities
Other financing activities
Net cash provided by (used in) financing activities

Effects of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash, beginning of period
Cash, cash equivalents, and restricted cash, end of period
Non-cash investing and financing activities:
Property, plant and equipment acquired but not paid
Unrealized (loss) gain on available-for-sale investments
Issuance of 162,606, 136,559, and 86,532 shares of common stock to fund the Company’s 401(k) matching contribution for 2020, 2019, and 2018, respectively
Issuance of 2,159,716 shares of common stock upon settlement of convertible notes
Issuance of 10,581,429, 386,293, and 17,046,159 shares of common stock in 2021, 2020, and 2019, respectively, for business combination
Business acquisition contingent consideration liability
Stock Issued During Period, Value, Employee Benefit Plan
Supplemental disclosure of cash flow information:
Interest paid

Reconciliation of cash, cash equivalents, and restricted cash:
Cash and cash equivalents
Restricted cash — included in other long-term assets, net

Comments